Labcorp Holdings（LH）FY2025年报排雷报告

框架：唐朝《手把手教你读财报》+ Schilit《Financial Shenanigans》+ Beneish M-Score

核心理念："财报是用来排除企业的"

数据来源：SEC EDGAR 10-K原文 + Yahoo Finance

❌ 评级F——现金覆盖和商誉集中

一句话：Labcorp的F评级来自两项结构性失败——$5.3亿现金仅覆盖$65.3亿总债务的8%，$103.9亿商誉+无形资产等于$86.2亿权益基数的120%。底层的实验室检测业务稳定：营收增长7.2%到$139.5亿、CFFO/NI 1.87（强劲）、FCF $12.1亿（健康）、毛利率扩张90bp（收入成本从72.1%降到71.2%）、SG&A杠杆改善。M-Score -2.55干净通过，债务/EBITDA 3.2x在诊断运营商可接受范围内。这是一份被并购驱动的资产负债表结构拖累的干净经营画像。

一、两个分部：诊断和生物制药实验室服务

Labcorp在2023年6月30日Fortrea分拆后运营两个分部：

诊断（Dx）——临床实验室检测业务，是Labcorp的历史核心。FY2025营收$10,876.5M，同比从$10,144.3M增长7.2%。

生物制药实验室服务（BLS）——为生物制药客户提供的中心实验室服务。FY2025营收$3,098.2M，同比从$2,922.6M增长6.0%。

MD&A："For the year ended December 31, 2025, the Company's revenues were $13,951.7, an increase of 7.2% from $13,008.9 for the corresponding period in 2024. The 7.2% increase in revenues for the year ended December 31, 2025, as compared to the corresponding period in 2024, was primarily due to organic revenue of 4.4%, acquisitions, net of divestitures of 2.5%, and favorable foreign currency translation of 0.4%."

MD&A的Dx分部增长拆分："Dx total volume, measured by requisitions, increased by 3.7%, as organic volume increased by 2.2% and acquisition volume, net of divestitures, contributed 1.5%. Price/mix increased by 3.5% due to organic growth of 1.9% and acquisitions, net of divestitures, of 1.7%, partially offset by unfavorable foreign currency translation of 0.1%."

量/价拆分令人鼓舞：量和价/组合对Dx增长的贡献大致相等，表明持续需求而非单纯定价。

成本效率改善

MD&A："Cost of revenues as a percentage of revenues decreased as a percentage of revenues to 71.2% for the year ended December 31, 2025, as compared to 72.1% for the corresponding period in 2024. This decrease was primarily due to operational efficiencies and the impact from revenue growth, including the performance of Invitae."

和："Selling, general, and administrative expenses as a percentage of revenues decreased to 15.9% for the year ended December 31, 2025, as compared to 17.1% for the year ended December 31, 2024. The decrease was primarily due to growth in demand as the Company leveraged the growth of its revenues and a decrease in costs related to the Spin-off."

收入成本加SG&A合计2.1pp的改善产生了约$2.9亿的运营杠杆——体现在营业利润从$11.4亿跳升到$15.2亿。

营业利润在7.2%营收增长下增长33%——这种运营杠杆是FY2025的故事。

二、现金流和资本资源

CFFO $16.4亿和FCF $12.1亿代表健康的现金转换——FCF覆盖净利润1.38倍。CFFO/NI比率1.87反映了大量折旧和摊销通过非现金运营调整流动。

三、18项排雷检查

收入质量

三项收入质量检查全部干净通过。DSO持平在55天，应收大致与营收同步增长，CFFO温和增长。

费用质量

毛利率扩张90bp——与MD&A披露的收入成本从72.1%降到71.2%一致。SG&A占毛利润55%对临床实验室来说典型——销售和客户服务承担重要固定间接成本。

现金流质量

C4是主要关键失败。$5.3亿现金对$65.3亿债务产生8%覆盖率——远低于50%阈值。然而，债务/EBITDA 3.2x，利息覆盖率舒适，公司每年产生$12.1亿FCF。绝对现金对债务比率未通过机械筛选，但底层债务偿还能力足够。

资产负债表

D1失败：商誉$67.9亿加其他无形资产$36.0亿 = $103.9亿合计，等于$86.2亿权益基数的120%。绝对数字从$98.6亿增长到$103.9亿——$5.3亿的增量反映并购活动。MD&A指出FY2025的"商誉和其他资产减值"仅$430万，所以增长全部来自收购。

并购风险

Beneish M-Score

四、10-K原文中的关键风险

1. 报销压力和支付方组合。 10-K首位风险："Continued changes in healthcare reimbursement models and products (e.g., health insurance exchanges), changes in government payment and reimbursement systems, or changes in payer mix, including an increase in third-party benefits management and value-based payment models, could have a material adverse effect on the Company's revenues, profitability, and cash flow."

2. OBBBA——一个大而美法案对Medicaid和ACA的影响。 MD&A："On July 4, 2025, the U.S. government enacted the OBBBA, which includes provisions addressing regulations and federal funding affecting healthcare. These provisions include, but are not limited to, changes to Medicaid and the ACA, and could lead to revised regulatory requirements and reduced federal funding. As a result of these changes, the Company could experience a decline in utilization of its diagnostics testing services due to a reduction in overall insurance coverage."

3. 宏观经济和需求周期性。 10-K："General or macro-economic factors and significant fluctuations in economic conditions in the U.S. and globally may have a material adverse effect on the Company. The Company's business depends on sustained demand for diagnostic testing and biopharma laboratory services by patients, physicians, hospitals, MCOs, CROs, pharmaceutical, biotechnology, medical device companies, and others."

4. 人员和劳动力成本压力。 "An inability to attract, retain, and develop experienced and qualified personnel, including personnel in key roles and critical positions, and increased personnel costs, could adversely affect the Company's business."

5. 网络安全事件（历史）。 10-K指出："In July 2018, the Company experienced a ransomwar[e]..."——提醒持有大量受保护健康信息的实验室运营商仍是高价值网络目标。

6. Dx分部应收估值（关键审计事项）。 Deloitte："The Company recognizes Dx revenue and accounts receivable net of negotiated discounts and anticipated adjustments, including historical collection experience for each of its four payer portfolios (clients, patients, Medicare & Medicaid, and third-party). Management has a formal process to estimate implicit price concessions for uncollectable accounts."

五、Altman Z-Score和F-Score

Z-Score 3.37舒适地超过2.60安全区阈值。杠杆有意义但EBITDA和营运资本支撑了分数。

六、总结

评级：F。十五项通过，两项机械失败在现金覆盖和商誉强度。

Labcorp运营着一个稳定、运营健康的实验室检测业务。FY2025数字显示了干净的执行：7.2%营收增长在量和价之间大致均分；收入成本改善90bp；SG&A杠杆120bp；营业利润增长33%；CFFO $16.4亿；FCF $12.1亿。M-Score -2.55和应计比率-4.2%未显示任何操纵信号。

F评级来自两项机械失败：

根据10-K和关键审计事项的真实风险是：（1）OBBBA驱动的Medicaid和ACA变化可能压缩诊断检测利用率；（2）来自支付方和政府计划的持续报销压力；（3）Dx分部应收估值——Deloitte明确指出跨四个支付方组合估计隐含价格让步所涉及的判断。盈利质量是干净的；资产负债表杠杆才是F评级所在。

财报是起点，不是终点。

⚠️ **免责声明**：本报告基于Labcorp 2025 10-K年报原文（SEC EDGAR）及Yahoo Finance公开财务数据，运用排雷框架进行分析，不构成任何投资建议。投资有风险，决策需自行判断。

数据来源：SEC EDGAR 10-K (Filed 2026-02-24) + Yahoo Finance

审计师：Deloitte & Touche LLP（无保留意见，1项关键审计事项）